| 영문 | stem cell | 한글 | 줄기세포, 간세포 |
|---|---|---|---|
| 설명 | 자기 복제를 하여 자신을 존속시키면서 한편으로는 증식과 분화를 하여 새로운 세포를 형성하는 세포로서 조혈줄기세포가 대표적이다. 조혈줄기세포는 골수에 있는 세포로서 모든 혈구세포가 여기에서 분화되어 발생한다. |
||
| 영문 | renal cell carcinoma | 한글 | 콩팥세포암종 |
|---|---|---|---|
| 설명 | 콩팥에 생긴 원시콩팥조직에서 발생한 암. 주로 원시세뇨관조직에서 발생한다. 대표적인 세포조직형은 염색시 세포질이 맑게 비어보이는 맑은세포암종이다. 치료는 수술과 항암화학요법이며 아주 드물지만 저절로 낫는 경우도 있는 것으로 보고되어 있다. |
||
| 영문 | squamous cell carcinoma | 한글 | 편평세포암종 |
|---|---|---|---|
| 설명 | 편평세포 기원의 암으로서, 편평세포가 있는 어떤 곳에서든 발생가능함. 따라서 식도암, 피부암, 폐암, 자궁암 등이 여기에 해당된다. 특히 피부암은 많은 자외선조사에 의해 생기는 광선각화증에서 발생가능하다. 병리조직학적 특성으로서 각질을 생성한다. |
||
| IAP | immunosuppressive acidic protein; inosinic acid pyrophosphorylase; Institute of Animal Physiology; i... |
|---|---|
| IAPP | International Association for Preventive Pediatrics; islet amyloid polypeptide |
| IPITA | International Pancreas and Islet Transplant Association |
| is | in situ; island; islet; isolated |
| LI | labeling index; lactose intolerance; lacunar infarct; lamellar ichthyosis; Langerhans islet; large i... |
| insulin-like growth factor I | <chemical> A well-characterised basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on somatotropin. It is believed to be mainly active in adults in contrast to insulin-like growth factor II, which is a major foetal growth factor. Chemical name: Insulin-like growth factor I (12 Dec 1998) |
|---|---|
| insulin-like growth factor II | <chemical> A well-characterised neutral peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like and mitogenic activities. The growth factor has a major, but not absolute, dependence on somatotropin. It is believed to be a major foetal growth factor in contrast to insulin-like growth factor I, which is a major growth factor in adults. Chemical name: Insulin-like growth factor II (12 Dec 1998) |
| insulin-like growth factors | Peptides whose formation is stimulated by growth hormone. These peptides bring about peripheral tissue effects of that hormone and have high (about 70%) homology to human insulin. Synonym: somatomedins. (05 Mar 2000) |
| insulin lipoatrophy | Dystrophic atrophy of subcutaneous tissues in diabetics at the site of frequent injections of insulin. Synonym: insulin lipoatrophy. (05 Mar 2000) |
| insulin lipodystrophy | Dystrophic atrophy of subcutaneous tissues in diabetics at the site of frequent injections of insulin. Synonym: insulin lipoatrophy. (05 Mar 2000) |
| insulin, protamine zinc | <chemical> A long-acting insulin with an approximate time of onset of 7 hours and duration of action 36 hours, consisting of bovine or pork insulin reacted with zinc chloride and protamine to form a protein complex from which insulin is slowly released. Pharmacological action: hypoglycaemic agents. Chemical name: Insulin protamine zinc (12 Dec 1998) |
| insulin pump | A device that delivers a continuous supply of insulin into the body. The insulin flows from the pump through a plastic tube that is connected to a needle inserted into the body and taped in place. Insulin is delivered at two rates: a low, steady rate (called the basal rate) for continuous day-long coverage, and extra boosts of insulin (called bolus doses) to cover meals or when extra insulin is needed. The pump runs on batteries and can be worn clipped to a belt or carried in a pocket. It is used by people with insulin-dependent diabetes. (09 Oct 1997) |
| insulin reaction | A sudden uncontrolled decline in the blood sugar due to effects of insulin. (27 Sep 1997) |
| insulin receptor | Areas on the outer part of a cell that allow the cell to join or bind with insulin that is in the blood. When the cell and insulin bind together, the cell can take glucose (sugar) from the blood and use it for energy. (09 Oct 1997) |
| insulin receptor protein-tyrosine kinase | <enzyme> A catalytic protein-tyrosine kinase domain found on the cytoplasmic beta-portion of the insulin receptor. Registry number: EC 2.7.1.- (12 Dec 1998) |
| insulin receptor substrate-1 protein | <chemical> Amino acid sequence given in first source; a 180 kD protein that contains multiple phosphorylated tyrosine residues after insulin stimulation; human and rat forms (hirs-1 and irs-1) are homologous Synonym: insulin receptor substrate-1-like protein, irs-1 protein, irs-1 gene product, hirs-1 protein, hirs-1 gene product, insulin receptor substrate 1, insulin receptor substrate-1 (05 Dec 1998) |
| insulin resistance | Many people with noninsulin-dependent diabetes produce enough insulin, but their bodies do not respond to the action of insulin. This may happen because the person is overweight and has too many fat cells, which do not respond well to insulin. Also, as people age, their body cells lose some of the ability to respond to insulin. Insulin resistance is also linked to high blood pressure and high levels of fat in the blood. Another kind of insulin resistance may happen in some people who take insulin injections. They may have to take very high doses of insulin every day (200 units or more) to bring their blood glucose (sugar) down to the normal range. (09 Oct 1997) |
| insulin shock | A severe condition that occurs when the level of blood glucose (sugar) drops quickly. The signs are shaking, sweating, dizziness, double vision, convulsions, and collapse. Insulin shock may occur when an insulin reaction is not treated quickly enough. See: hypoglycaemia. (09 Oct 1997) |
| insulin shock treatment | Formerly used treatment for serious mental disorders in which the patient was given insulin to induce a seizure; supplanted by electroshock therapy. (05 Mar 2000) |
| insulin-stimulating peptide | <chemical> 71-amino acid containing peptide; corresponds to residues 115-143 and 144-184 of bovine serum albumin with the exception of a tyrosine insertion between residues 155 and 156; consists of two chains with mw 5000 and 3400 for each chain Synonym: h-isp, insulin-stimulating protein (05 Dec 1998) |